A clinicopathological study and prognostic factor analysis of 177 salivary duct carcinoma patients from The Netherlands
Open Access
- 23 March 2018
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 143 (4), 758-766
- https://doi.org/10.1002/ijc.31353
Abstract
Salivary duct carcinoma (SDC) is a subtype of salivary gland cancer with a dismal prognosis and a need for better prognostication and novel treatments. The aim of this national cohort study was to investigate clinical outcome, prognostic factors, Androgen Receptor (AR) and Human Epidermal Growth Factor Receptor 2 (HER2) expression. SDC patients diagnosed between 1990 – 2014 were identified by the Nationwide Network and Registry of Histo- and Cytopathology in the Netherlands (PALGA). Subsequently, medical records were evaluated and pathological diagnoses reviewed. Data were analyzed for overall survival (OS), disease free survival (DFS), distant metastasis free survival (DMFS), and prognostic factors. AR was evaluated by immunohistochemistry (IHC), HER2 by IHC and fluorescent-in-situ-hybridization. A total of 177 patients were included. The median age was 65 years, 75% were male. At diagnosis, 68% presented with lymph node metastases and 6% with distant metastases. Median OS, DFS and DMFS were 51, 23 and 26 months, respectively. In patients presenting without distant metastases, the absolute number of positive lymph nodes was associated with poor OS and DMFS in a multivariable analysis. AR and HER2 were positive in 161/168 (96%) and 44/153 (29%) tumors, respectively, and were not prognostic factors. SDC has a dismal prognosis with primary lymph node involvement in the majority of patients. The absolute number of lymph node metastases was found to be the only prognostic factor for DMFS and OS. AR expression and, to a lesser extent, HER2 expression hold promise for systemic treatment in the metastatic and eventually adjuvant setting.This publication has 21 references indexed in Scilit:
- Prognostic value of lymph node density in high‐grade salivary gland cancersJournal of Surgical Oncology, 2015
- Prognostic factors and oncologic outcomes of 56 salivary duct carcinoma patients in a single institution: High rate of systemic failure warrants targeted therapyOral Oncology, 2014
- Clinicopathological significance of androgen receptor, HER2, Ki-67 and EGFR expressions in salivary duct carcinomaInternational Journal of Clinical Oncology, 2014
- Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline UpdateJournal of Clinical Oncology, 2013
- Survival rates and prognostic factors for infiltrating salivary duct carcinoma: Analysis of 228 cases from the Surveillance, Epidemiology, and End Results databaseHead & Neck, 2013
- Detection of Novel Actionable Genetic Changes in Salivary Duct Carcinoma Helps Direct Patient TreatmentClinical Cancer Research, 2013
- Androgen Receptor–Positive Salivary Duct Carcinoma: A Disease Entity With Promising New Treatment OptionsJournal of Clinical Oncology, 2011
- Treatment relevant target immunophenotyping of 139 salivary gland carcinomas (SGCs)Oral Oncology, 2009
- WHO International Histological Classification of Tumours Tentative Histological Classification of Salivary Gland TumoursPathology - Research and Practice, 1990
- SpeichelgangcarcinomeEuropean Archives of Oto-Rhino-Laryngology, 1968